Suppr超能文献

反式-6-氰基-4-(N-乙基磺酰基-N-甲基氨基)-3-羟基-2,2-二甲基苯并二氢吡喃的分子靶点是KvLQT1钾通道而非IsK。

KvLQT1 potassium channel but not IsK is the molecular target for trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl- chromane.

作者信息

Loussouarn G, Charpentier F, Mohammad-Panah R, Kunzelmann K, Baró I, Escande D

机构信息

Laboratoire de Physiopathologie et de Pharmacologie Cellulaires et Moléculaires, Institut National de la Santé et de la Recherche Médicale CJF96-01, Hôpital Hotel-Dieu, Nantes, France.

出版信息

Mol Pharmacol. 1997 Dec;52(6):1131-6. doi: 10.1124/mol.52.6.1131.

Abstract

Mutations in the KvLQT1 gene are the cause for the long QT syndrome [Circulation 94:1996-2012 (1996)]. Coexpression of KvLQT1 in association with the channel regulator protein IsK produces a K+ current with characteristics reminiscent of the slow component of the delayed rectifier in cardiac myocytes. We explored the pharmacological properties of trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dime thyl- chromane (293B), a chromanol compound, on the K+ current produced by direct intranuclear injection of KvLQT1 and IsK cDNA plasmids in COS-7 cells. Injected cells were recorded by means of the whole-cell and cell-attached patch-clamp configurations under chloride-free conditions. Cells injected with KvLQT1 cDNA alone exhibited a fast-activating outward K+ current, whereas cells coinjected with KvLQT1 plus IsK cDNAs exhibited a time-dependent outward current with slower activation kinetics. The chromanol 293B blocked the K+ current related to KvLQT1 expression in both the absence or presence of IsK. The IC50 value for 293B to block KvLQT1-related current was not significantly modified by the presence of IsK (9.9 microM in the absence of IsK versus 9.8 microM in its presence). The block produced by 293B was strongly voltage-dependent inasmuch as it was close to 0 at -80 mV and occurred during a depolarizing voltage step. The time constants for the drug to block the current were in the same order of magnitude as activation kinetics of the current. Kinetics for drug unblock at the holding potential were much faster, in the order of a few tenths of a msec. KvLQT1 currents recorded in the cell-attached configuration were also blocked by externally applied 293B, suggesting that the compound penetrated the cell to block the channel. Cromakalim, another chromanol compound, also blocked KvLQT1 currents. Our results show that the chromanol compound 293B is targeted to KvLQT1 channels but not to the IsK regulator.

摘要

KvLQT1基因突变是长QT综合征的病因[《循环》94:1996 - 2012(1996)]。KvLQT1与通道调节蛋白IsK共表达可产生一种钾电流,其特性让人联想到心肌细胞中延迟整流器的慢成分。我们研究了反式-6-氰基-4-(N-乙基磺酰基-N-甲基氨基)-3-羟基-2,2-二甲基苯并二氢吡喃(293B),一种苯并二氢吡喃类化合物,对通过在COS-7细胞中直接核内注射KvLQT1和IsK cDNA质粒产生的钾电流的药理特性。在无氯条件下,通过全细胞和细胞贴附式膜片钳配置记录注射后的细胞。单独注射KvLQT1 cDNA的细胞表现出快速激活的外向钾电流,而同时注射KvLQT1加IsK cDNA的细胞表现出具有较慢激活动力学的时间依赖性外向电流。苯并二氢吡喃类化合物293B在有无IsK的情况下均能阻断与KvLQT1表达相关的钾电流。293B阻断KvLQT1相关电流的IC50值不受IsK存在的显著影响(无IsK时为9.9微摩尔,有IsK时为9.8微摩尔)。293B产生的阻断强烈依赖电压,因为在-80 mV时接近0,且在去极化电压阶跃期间发生。药物阻断电流的时间常数与电流的激活动力学处于同一数量级。在保持电位下药物解除阻断的动力学要快得多,约为几十分之一毫秒。在细胞贴附配置中记录的KvLQT1电流也被外部施加的293B阻断,这表明该化合物穿透细胞以阻断通道。另一种苯并二氢吡喃类化合物克罗卡林也能阻断KvLQT1电流。我们的结果表明,苯并二氢吡喃类化合物293B作用于KvLQT1通道而非IsK调节蛋白。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验